Comparison · NCT01940523-32a5cd36
IV TXA Group vs Topical TXA Group: The Number Patients Requiring a Transfusion
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IV TXA Group vs Topical TXA Group: The Number Patients Requiring a Transfusion. Trial comparisons, record NCT01940523-32a5cd36. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01940523-32a5cd36
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00625 | 0.00172 | 0.0225 | wilson | |
| Risk in group 2 | 0.0188 | 0.00862 | 0.0403 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0125 | -0.0345 | 0.00665 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.333 | 0.0678 | 1.64 | log | |
| Odds ratio, group 1 over group 2 | 0.329 | 0.0659 | 1.64 | log | |
| Number needed to treat, for one fewer participant with the outcome on IV TXA Group than on Topical TXA Group | 80 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IV TXA Group | Kaitlin - Explain this group.... | 2 | 320 | OG000 |
| Group 2 | Topical TXA Group | Kaitlin - Explain this group | 6 | 320 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Number Patients Requiring a Transfusion
- Description
- TThe number Patients requiring a transfusion over the course of the patient's hospital stay.
- Time frame
- over course of hospital stay (averaging three days)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical
- NCT number
- NCT01940523
- Phases
- PHASE4
- Conditions
- Osteoarthritis
- Interventions
- Topical Tranexamic Acid, Intravenous Tranexamic Acid
- Lead sponsor
- Hospital for Special Surgery, New York
- Results first posted
- 2017-06-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01940523?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01940523-32a5cd36